['thyroid carcinoma']
['sorafenib (nexavar,bay43-9006)']

        Inclusion Criteria:

          -  Japanese patients with ATC (Anaplastic thyroid carcinoma) or locally advanced or
             metastatic MTC (medullary thyroid carcinoma)

          -  Not a candidate for surgery or radiotherapy with curative intent

          -  Histologically or cytologically confirmed ATC or MTC

          -  Measurable or non-measurable disease (but clinically evaluable) according to RECIST
             1.1.

          -  Age >= 18 years

          -  Adequate bone marrow, liver and renal function to be conducted within 14 days prior to
             treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma

          -  Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies
             (licensed or investigational) that target VEGF or VEGF (vascular endothelial growth
             factor) receptors or other targeted agents

          -  Prior chemotherapy for thyroid cancer (only one regimen is allowed)

          -  Major surgery, open biopsy, or significant traumatic injury within 30 days prior to
             enrollment in the study.

          -  Subjects with tracheal, bronchial or esophageal infiltration with significant risk of
             bleeding but without having received local treatment prior to enrollment in the study
      